Sanguine Difference
The Sanguine Difference
By simplifying the donation process, we have built a highly-engaged group of donors for minimally-invasive biospecimens.
Our Success In Numbers
2000+
Completed
Studies
93%
Delivered to Plan
25+
Top Pharma
Clients
100+
Nonprofit Organization Partnerships
70,000+
Donor Community
- Donor Access and Engagement
Strategies for reach, recruitment, retention
Geographic and demographic diversity
Diversity of disease states
Donor Centric
- Study Design Capabilities
Sample collection
Participant retention
(longitudinal studies)Donor Data
Post-collection processing
- Clinically Relevant Annotated Specimens
Sample integrity
Samples and data collected by Sanguine
Longitudinal sampling
Simultaneous collection of multiple specimen types
Large volume collection (≤180 mL)
Patient-reported outcomes data
(PRO, ePRO)Same-day sample collection and delivery
- Specialty Biospecimen Collection
Leukopaks (leukocyte-enriched apheresis products)
Healthy specimens collected at client’s facilities
Direct Donor Access
Sanguine Model
- Donor Access and Engagement
-
Strategies for reach, recruitment, retention Mobile, virtual, flexible
-
Geographic and demographic diversity Nationwide, urban or rural
-
Diversity of disease states Broad with over 100 diagnosed conditions
-
Donor Centric Engaged homegrown communities
- Study Design Capabilities
-
Sample collection Prospective
-
Participant retention
(longitudinal studies) High retention rates >95% -
Donor Data FHIR electronic health records, demographics, ability to add surveys, questionnaires, and outcomes
-
Post-collection processing Customize parameters and procedures
- Clinically Relevant Annotated Specimens
-
Sample integrity
-
Samples and data collected by Sanguine
-
Longitudinal sampling
-
Simultaneous collection of multiple specimen types
-
Large volume collection (≤180 mL)
-
Patient-reported outcomes data
(PRO, ePRO) -
Same-day sample collection and delivery
- Specialty Biospecimen Collection
-
Leukopaks (leukocyte-enriched apheresis products)
-
Healthy specimens collected at client’s facilities
Indirect Donor Access
Biobanks and other providers
- Donor Access and Engagement
-
Strategies for reach, recruitment, retention Confined, brick and mortar
-
Geographic and demographic diversity Limited by access to medical facility
-
Diversity of disease states Typically oncology-focused
-
Donor Centric Third-party mediated, transactional
- Study Design Capabilities
-
Sample collection Retrospective
-
Participant retention
(longitudinal studies) Low or no retention -
Donor Data Often limited to demographics or possibly medical records
-
Post-collection processing Limited to how specimens were initially collected
- Clinically Relevant Annotated Specimens
-
Sample integrity
-
Samples and data collected by Sanguine
-
Longitudinal sampling
-
Simultaneous collection of multiple specimen types
-
Large volume collection (≤180 mL)
-
Patient-reported outcomes data
(PRO, ePRO) -
Same-day sample collection and delivery
- Specialty Biospecimen Collection
-
Leukopaks (leukocyte-enriched apheresis products) Specialty vendors
-
Healthy specimens collected at client’s facilities

Access challenging, hard-to-collect samples
Sanguine's unique donor-centric approach to biospecimen collection gives researchers access to rare populations and complex study designs such as event-based collection, longitudinal collections, and more.
Are you a researcher?
Find out how Sanguine can accelerate your study.